Everything below concerns lipogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-12. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Blood sugar regulation is the process by which the level of blood sugar, the common name for glucose dissolved in blood plasma, is maintained by the body within a narrow range. This tight regulation is referred to as glucose homeostasis. Insulin, which lowers blood sugar, and glucagon, which raises it, are the most well known of the hormones involved, but more recent discoveries of other glucoregulatory hormones have expanded understanding of this process. The pancreas gland secretes two hormones that are primarily responsible for regulation of glucose levels in blood.
==== Homosexuality ==== Dr. Diana Fleischman, of the University of Portsmouth, and colleagues looked for a relationship between progesterone and sexual attitudes in 92 women. Their research, published in the Archives of Sexual Behavior found that women who had higher levels of progesterone scored higher on a questionnaire measuring homoerotic motivation. They also found that men who had high levels of progesterone were more likely to have higher homoerotic motivation scores after affiliative priming compared to men with low levels of progesterone.
In Korea, pubic hair has long been considered a sign of fertility and sexual health, and it has been reported in the mid-2010s that some Korean women were undergoing pubic hair transplants, to add extra hair, especially when affected by the condition of pubic atrichosis (or hypotrichosis), which is thought to affect a small percentage of Korean women. Unwanted or excessive hair is often removed in preparatory situations by both sexes, in order to avoid any perceived social stigma or prejudice. For example, unwanted or excessive hair may be removed in preparation for an intimate encounter, or before visiting a public beach or swimming pool. Though traditionally in Western culture women remove body hair and men do not, some women choose not to remove hair from their bodies, either as a non-necessity or as an act of rejection against social stigma, while some men remove or trim their body hair, a practice that is referred to in modern society as being a part of "manscaping" (a portmanteau expression for male-specific grooming).
Biological research in cold seeps and hydrothermal vents has been mostly focused on the microbiology and the prominent macro-invertebrates thriving on chemosynthetic microorganisms. Much less research has been done on the smaller benthic fraction at the size of the meiofauna (<1 mm). A community composition's orderly shift from one set of species to another is called ecological succession. The first type of organism to take advantage of this deep-sea energy source is bacteria. Aggregating into bacterial mats at cold seeps, these bacteria metabolize methane and hydrogen sulfide (another gas that emerges from seeps) for energy. This process of obtaining energy from chemicals is known as chemosynthesis.
=== Other === Intravaginal administration Vaginal rings Capsules and tablets Suppositories Rectal administration (enteral) Suppositories Suspensions and solutions in the form of enemas Gels Urethral Nasal sprays
Sources: en.wikipedia.org
=== Diagnostic use === CRP is used mainly as an inflammation marker. Apart from liver failure, there are few known factors that interfere with CRP production. Interferon alpha inhibits CRP production from liver cells which may explain the relatively low levels of CRP found during viral infections compared to bacterial infections Measuring and charting CRP values can prove useful in determining disease progress or the effectiveness of treatments. ELISA and radial immunodiffusion methods are available for research use, while immunoturbidimetry is used clinically for CRP and nephelometry is typically used for hsCRP. Cutoffs for cardiovascular risk assessment have included:
The one-stepwise pyrolysis experiment showed different results for the CO2 and N2 environments. During this process the evolution of 5 different notable gases were observed. Hydrogen, Methane, Ethane, Carbon Dioxide, and Ethylene all are produced when the thermolytic rate of TLW began to be retarded at greater than or equal to 500 °C. Thermolytic rate begins at the same temperatures for both the CO2 and N2 environment but there is higher concentration of the production of Hydrogen, Ethane, Ethylene, and Methane in the N2 environment than that in the CO2 environment. The concentration of CO in the CO2 environment is significantly greater as temperatures increase past 600 °C and this is due to CO2 being liberated from CaCO3 in TLW. This significant increase in CO concentration is why there is lower concentrations of other gases produced in the CO2 environment due to a dilution effect. Since pyrolysis is the re-distribution of carbons in carbon substrates into three pyrogenic products. The CO2 environment is going to be more effective because the CO2 reduction into CO allows for the oxidation of pyrolysates to form CO. In conclusion the CO2 environment allows a higher yield of gases than oil and biochar. When the same process is done for TSW the trends are almost identical therefore the same explanations can be applied to the pyrolysis of TSW. Harmful chemicals were reduced in the CO2 environment due to CO formation causing tar to be reduced.
Its main adverse effects are linked to infusion-site reactions which, even though mild to moderate, are responsible for early discontinuation. Levodopa-carbidopa microtablets (LC-5), marketed as Flexilev, are small dispersible low-dose tablets consisting of 5 mg levodopa and 1.25 carbidopa per tablet. The tablets are designed for frequent oral dosing throughout the day in order to maintain stable levodopa concentrations in the blood via fine granularity. Pharmacokinetic studies demonstrated the bioequivalence of LC-5 to standard levodopa/carbidopa tablets and showed that fractionated administration reduce the fluctuations of plasmatic levodopa while keeping high adherence, symptoms improvement and lower cost estimates. Because the main challenge for the patients using LC-5 is linked to the intake of frequent small doses which can be impractical, the microtablets are paired with a device for their administration. The first device was an electronic dispenser with touch-screen called MyFID, loaded with 750 microtablets in a cassette and capable of notifying the patients with alerts. The new completely mechanic device, OraFID, is pre-filled with 2250 microtablets and enables accurate dosing.
== Legal matters == In 2022, Ashley & Martin sued Pilot in Federal Court over online advertising claims made in September-October. They initially sought compensation for false and misleading representations by Pilot. They also sought an interim injunction to force Pilot to take down the allegedly misleading and deceptive advertising, which was withdrawn the day after Pilot officially appointed a legal team to defend the case. They further asked for compensation under Australian Competition Law, a permanent injunction preventing Pilot from breaching the misleading and deceptive product conduct rules, court declarations that Pilot's claims were deceptive and corrective notices published where ads appeared. The case was scheduled before Justice Darren Jackson on December 7, 2022.
=== Glassware === Silanization (or siliconization) of glassware is a common application that increases the hydrophobicity of a glass container. Thus treated, the glassware produces a flat meniscus and allowing for more complete transfer of aqueous solutions. Silanization of glassware is used in cell culturing to minimize adherence of cells to flask walls. Additionally, the silanization process is also used in biomedical fields for a wide variety of purposes, including anchoring DNA to substrates. Silanization of glassware can be achieved by dipping into a solution of 5-10% dimethyldiethoxysilane followed by heating. Silanization is also used for DNA chips. Nucleic acids do not bond to untreated glass surfaces. Silanization can be providing a better bonding site for the nucleic acids onto the chip. A common silane used to treat glass surfaces for this application is (3-mercaptopropyl)trimethoxysilane, which increases the number of reactive thiol groups on the surface The nucleic acids can bond to these available thiol groups on the surface of the glass DNA chip after silanization occurs.
Sources: en.wikipedia.org
== External links == Shityakov, Sergey; Salvador, Ellaine; Pastorin, Giorgia; Förster, Carola (2015). "Blood-brain barrier transport studies, aggregation, and molecular dynamics simulation of multiwalled carbon nanotube functionalized with fluorescein isothiocyanate". International Journal of Nanomedicine. 10: 1703–1713. doi:10.2147/IJN.S68429. PMC 4356663. PMID 25784800.
== Challenges == Despite the considerable investments made by several companies, proteins chips have yet to flood the market. Manufacturers have found that proteins are actually quite difficult to handle. Production of reliable, consistent, high-throughput proteins that are correctly folded and functional is fraught with difficulties as they often result in low-yield of proteins due to decreased solubility and formation of inclusion bodies. A protein chip requires a lot more steps in its creation than does a DNA chip. There are a number of approaches to this problem which differ fundamentally according to whether the proteins are immobilised through non-specific, poorly defined interactions, or through a specific set of known interactions. The former approach is attractive in its simplicity and is compatible with purified proteins derived from native or recombinant sources but suffers from a number of risks. Most notable amongst these relate to the uncontrolled nature of the interactions between each protein and the surface; at best, this might give rise to a heterogeneous population of proteins in which active sites are sometimes occluded by the surface; at worst, it might destroy activity altogether due to partial or complete surface-mediated unfolding of the immobilised protein.
=== Addiction === The KOR system is involved in increased drug-seeking behavior. KOR agonists have been investigated for their therapeutic potential in the treatment of addiction. and evidence points towards dynorphin peptides, the endogenous KOR agonists, to be the body's natural addiction control mechanism. Childhood stress and abuse are well-known predictors of drug abuse which is reflected in alterations of the MOR and KOR systems. In experimental "addiction" models the KOR has also been shown to influence stress-induced relapse to drug seeking behavior. For the drug-dependent individual, risk of relapse is a major obstacle to becoming drug-free. Recent reports demonstrated that KORs are required for stress-induced reinstatement of cocaine seeking. The nucleus accumbens (NAcc) and broader striatum are among the brain regions most strongly associated with addiction, although other structures that project to and from the NAcc also play critical roles in addictive processes. Though many other changes occur, addiction is often characterized by the reduction in the availability of dopamine D2 receptors in the NAcc. In addition to decreasing NAcc D2 binding, cocaine is also known to produce a variety of changes to the primate brain such as increases of prodynorphin mRNA in caudate putamen and decreases of the same polypeptide in the hypothalamus. The administration of a KOR agonist produced an opposite effect, causing an increase in D2 receptor availability in the NAcc.
== External links == Ethoxymethyl salvinorin B - Isomer Design Salvinorin B Ethoxymethyl Ether Reports - Erowid Experience Vaults - Erowid The Three Day Salvia Trip...? - Alien Insect on Drugs (Andrew Gallimore) - Substack
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.